A Randomized, Double-blind, Multicenter, Phase 2 Study of a Human Monoclonal Antibody to Human av Integrins (CNTO 95) in Combination With Docetaxel for the First-Line Treatment of Subjects With Metastatic Hormone Refractory Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2016
At a glance
- Drugs Intetumumab (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Centocor
- 31 Aug 2018 Biomarkers information updated
- 09 May 2012 New source identified and integrated (German Clinical Trials Register record, DRKS00003882).
- 24 Feb 2010 Actual end date (November 2009) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History